Verification of Fresenius Medical Care Share Sale Announcement Unavailable; Stakeholder Sold 7.8 Million Shares in August
Key Facts
The planned Fresenius announcement of a sale of shares in Fresenius Medical Care could not be verified from an open original source, so the transaction details cannot be confirmed or linked to a specific plan to reduce the stake. Fresenius Medical Care shares, listed under ticker FMS, closed at $22.74 on November 10, 2026, while FSNUY closed at $15.01 in the same session. Both figures reflect the close on the day before the news date and do not, on their own, establish the direction of the market’s response to the sale announcement. On August 20, 2026, Fresenius announced the sale of 7.8 million shares in the medical company to selected institutional investors for about 300 million euros. The company said at the time that the transaction would strengthen its balance sheet and increase its strategic flexibility.
The results come as Fresenius Medical Care reported revenue of 4,937 million euros in the third quarter of 2026, up 1% year on year, but down 1% on a constant-currency basis. Organic growth was 0.1%, the company said. In the same period, reported operating income fell 19% to 384 million euros. Operating income excluding special items declined 5% to 545 million euros, or 6% on a constant-currency basis. The indicators show a divergence between reported revenue growth and weaker operating profitability in the quarter.
The company’s net income fell 42% year on year to 160 million euros in the third quarter of 2026, and declined 41% on a constant-currency basis. The company kept its full-year revenue outlook broadly stable compared with the previous year. But it narrowed its operating income growth outlook, saying it would range from flat to a mid-single-digit percentage decline. This guidance sets a more cautious ceiling for full-year operating income performance than was available before the outlook update. The available data did not directly link this outlook to the share sale announcement.
The sale announced in August is a recent precedent for Fresenius reducing its holding in Fresenius Medical Care; the company said proceeds of about 300 million euros would reduce the group’s net debt and enable investment in the future. At the same time, Fresenius Medical Care had a share buyback program for 2026 and 2027 with a total value of about 1 billion euros, through tranches to be carried out within 12 months of the program’s start. The program page said the company had bought 11,252,037 shares as of the page’s update date. The available information does not explain how the program would be reconciled with the ongoing sale announcement, or how any new transaction would affect Fresenius’s ownership stake. The offering price and execution date still require a reliable disclosure confirming their details.